Genomic profiling improves cost-effectiveness by identifying non-responders to targeted therapy

The review examines the economic impact of precision oncology, noting that next-generation sequencing is becoming more cost-efficient than sequential single-gene assays. Investigators highlight that while matched targeted drugs often carry high price tags, broad genomic profiling can improve value by sparing patients from ineffective treatments. The authors also suggest that universal and germline cancer testing may offer better cost-effectiveness than traditional family-history-based approaches. For laboratory directors, these findings underscore the growing financial rationale for adopting comprehensive molecular testing algorithms over single-marker assays.